Biomea Fusion's Icovamenib Shows Promising Results in Type 2 Diabetes Treatment

Biomea Fusion presented new data on its oral menin inhibitor, icovamenib, at the American Diabetes Association's 85th Scientific Sessions. The drug showed a 1.0% placebo-adjusted reduction in HbA1c levels and a 55% increase in C-peptide among insulin-deficient patients. Icovamenib combined with low-dose semaglutide reduced fasting blood glucose by 60% and demonstrated good tolerability and sustained efficacy even three months post-treatment. The findings suggest icovamenib's potential to enhance existing GLP-1 receptor agonist therapies and improve metabolic outcomes in type 2 diabetes treatment.

Biomea Fusion, Inc. (Nasdaq: BMEA) presented new preclinical and clinical data on its oral menin inhibitor, icovamenib, at the 85th Scientific Sessions of the American Diabetes Association (ADA) in Chicago. The company showcased three abstracts highlighting icovamenib’s therapeutic potential in type 2 diabetes (T2D) management.

In a rodent model of T2D, icovamenib combined with low-dose semaglutide demonstrated enhanced glycemic control and body weight reduction, outperforming semaglutide alone [1]. The combination therapy resulted in a 60% reduction in fasting blood glucose, a 50% reduction in glucose OGTT AUC, and a significant improvement in insulin sensitivity, as measured by a 75% lower HOMA-IR. The study also showed a 2-fold increase in the C-peptide to glucose ratio, indicating enhanced beta cell function, and superior appetite suppression with a 10% greater body weight reduction than semaglutide alone.

In a separate study, icovamenib diminished drug-induced atrophy in ex vivo human myotube cultures, suggesting muscle health-supporting effects [1]. Additionally, the combination of icovamenib and semaglutide induced greater body weight reduction with complete preservation of lean mass in a ZDF rat model of diabetes, further supporting the potential of icovamenib to enhance the therapeutic effects of GLP-1-based therapies.

The Phase II COVALENT-111 trial presented at ADA 2025 showed that icovamenib achieved a 1.0% placebo-adjusted mean HbA1c reduction and a 55% increase in C-peptide in severe insulin-deficient participants at Week 26, three months after the last dose [1]. The study also demonstrated sustained HbA1c reductions through Week 26 and improved beta cell function, with over half of the C-peptide improvement occurring during the off-treatment period. Icovamenib was well tolerated across all dosing arms, with a low incidence of treatment-emergent adverse events.

These findings suggest that icovamenib, when combined with existing GLP-1 receptor agonist therapies, could enhance metabolic outcomes and improve glycemic control in T2D patients. The company remains committed to advancing novel therapies that improve patient outcomes in diabetes and obesity.

References:
[1] https://www.globenewswire.com/news-release/2025/06/23/3103243/0/en/Biomea-Fusion-Presents-New-Preclinical-and-Clinical-Data-on-Icovamenib-at-the-85th-Scientific-Sessions-of-the-American-Diabetes-Association-ADA.html